Additionally, higher expression of ER, PR, and Ki67 but similar trends for pathological type, tumor size, and nodal involvement were found in cHER2+ patients compared with those without cHER2+ CTCs (p = 0.569, 0.484, 0.780, 1.000, 0.900, and 0.927, respectively) (Figures 3I-P). This evidence concerns the gene ESR1 and neoplasm.